196 related articles for article (PubMed ID: 30287916)
21. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
22. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
23. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
24. Differential gene expression in ovarian carcinoma: identification of potential biomarkers.
Hibbs K; Skubitz KM; Pambuccian SE; Casey RC; Burleson KM; Oegema TR; Thiele JJ; Grindle SM; Bliss RL; Skubitz AP
Am J Pathol; 2004 Aug; 165(2):397-414. PubMed ID: 15277215
[TBL] [Abstract][Full Text] [Related]
25. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
26. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.
Zhang X; Wang X; Song X; Wei Z; Zhou C; Zhu F; Wang Q; Ma C; Zhang L
Oncol Rep; 2011 Feb; 25(2):353-8. PubMed ID: 21165576
[TBL] [Abstract][Full Text] [Related]
27. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
28. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
[TBL] [Abstract][Full Text] [Related]
29. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread.
Loessner D; Rizzi SC; Stok KS; Fuehrmann T; Hollier B; Magdolen V; Hutmacher DW; Clements JA
Biomaterials; 2013 Oct; 34(30):7389-400. PubMed ID: 23827191
[TBL] [Abstract][Full Text] [Related]
30. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
Miao Y; Cai B; Liu L; Yang Y; Wan X
Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
[TBL] [Abstract][Full Text] [Related]
32. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
33. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
34. Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival.
Batra J; Tan OL; O'Mara T; Zammit R; Nagle CM; Clements JA; Kedda MA; Spurdle AB
Int J Gynecol Cancer; 2010 May; 20(4):529-36. PubMed ID: 20686372
[TBL] [Abstract][Full Text] [Related]
35. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Dong Y; Stephens C; Walpole C; Swedberg JE; Boyle GM; Parsons PG; McGuckin MA; Harris JM; Clements JA
PLoS One; 2013; 8(2):e57056. PubMed ID: 23451143
[TBL] [Abstract][Full Text] [Related]
37. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
38. Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Zhang SQ; Cai B; Liu L; He YY; Yang YX; Wan XP
Int J Gynecol Cancer; 2009 Nov; 19(8):1377-83. PubMed ID: 20009893
[TBL] [Abstract][Full Text] [Related]
39. Profiling of selected angiogenesis-related genes in serous ovarian cancer patients.
Kuć P; Charkiewicz R; Klasa-Mazurkiewicz D; Milczek T; Mroczko B; Nikliński J; Laudański P
Adv Med Sci; 2017 Mar; 62(1):116-120. PubMed ID: 28235714
[TBL] [Abstract][Full Text] [Related]
40. Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.
Papachristopoulou G; Talieri M; Scorilas A
Tumour Biol; 2013 Feb; 34(1):369-78. PubMed ID: 23086576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]